NTLA peer analysis
Intellia (NTLA) against its competitors: price, today's move, 1-year return and market value side by side.
NTLA and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| BEAM Beam Therapeutics | $25.86 | -5.03% | 8.66% | $2.81B |
| CRBU Caribou Biosciences | $0.42 | -4.90% | -81.76% | – |
| CRSP CRISPR Therapeutics | $49.57 | -3.60% | -18.87% | $4.97B |
| EDIT Editas Medicine | $2.57 | -3.75% | -14.62% | $410.06M |
| MGTX MeiraGTx | $9.49 | -2.22% | 8.71% | $911.45M |
| MGX Metagenomi Therapeutics | $0.78 | -6.01% | -68.02% | – |
| PGEN Precigen | $5.19 | -25.22% | 28.15% | $2.48B |
| QURE uniQure | $22.97 | -7.49% | -66.15% | $1.72B |
| RCKT Rocket Pharmaceuticals | $2.44 | -3.94% | -34.05% | $267.85M |
| SANA Sana | $2.57 | -5.51% | -47.55% | – |
| NTLA Intellia | $11.67 | -6.42% | -4.85% | $1.75B |
- NTLA's peers: BEAM (Beam Therapeutics), CRBU (Caribou Biosciences), CRSP (CRISPR Therapeutics), EDIT (Editas Medicine), MGTX (MeiraGTx), MGX (Metagenomi Therapeutics), PGEN (Precigen), QURE (uniQure).
Updated 2026-11-03 00:58 UTC